Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Brentuximab Vedotin Boosts Survival in Adult and AYA Patients with Advanced Hodgkin Lymphoma

July 20th 2022

Ann S. LaCasce, MD, MMSC, explains how bretuximab vedotin has produced a survival benefit in patients with advanced classic Hodgkin lymphoma.

Dr. Phillips on p53 Mutations in MCL

July 20th 2022

Tycel Jovelle Phillips, MD, discusses the role of p53 mutations in the outcomes of patients with mantle cell lymphoma.

Dr. Kallam on the Role of BTK and PI3K Inhibitors in CNS Lymphoma

July 20th 2022

Avyakta Kallam, MBBS, discusses the role of BTK and PI3K inhibitors in the treatment of patients with central nervous system lymphoma.

Dr. Mehta-Shah on the Variations of the CHOP Regimen in PTCL

July 20th 2022

Neha Mehta-Shah, MD, MSCI, discusses variations of CHOP-based chemotherapy in peripheral T-cell lymphoma.

Mosunetuzumab Monotherapy Generates Promising Responses in Relapsed/Refractory Follicular Lymphoma

July 20th 2022

Single-agent mosunetuzumab produced a complete response rate that was greater than what has been observed with historical controls in patients with relapsed/refractory follicular lymphoma who had received at least 2 prior lines of therapy, meeting the primary end point of the expansion portion of the phase 1/2 GO29781 trial.

Dr. Kahl on the Evolving Standard of Care in MCL

July 20th 2022

Brad S. Kahl, MD, discusses current best practices for the treatment of older patients with mantle cell lymphoma, as well as where the treatment paradigm might lead in the future.

Rituximab Maintenance Therapy Continues to Provide Remission Benefit in MCL

July 20th 2022

Brad S. Kahl, MD, explains the evolution of mantle cell lymphoma treatment over the past decade and lays out the trajectory for future therapies, including the potential benefits of lenalidomide in the maintenance setting.

Zanubrutinib Showcases Superior PFS Benefit Over BR in Treatment-Naïve CLL/SLL, Including High-Risk Subsets

July 20th 2022

Zanubrutinib was found to significantly improve progression-free survival over a doublet comprised of bendamustine plus rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from cohort 1 of the phase 3 SEQUOIA trial.

CB-010 Exhibits Impressive Early Efficacy in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

July 20th 2022

The CAR T-cell therapy CB-010 displayed promising preliminary efficacy and safety results in patients with relapsed/refractory B-cell non-Hodgkin lymphoma according to findings from the phase 1 ANTLER trial presented during the 2022 Pan Pacific Lymphoma Meeting.

Polatuzumab Vedotin Plus R-CHP Significantly Extends PFS in Untreated DLBCL

July 19th 2022

Polatuzumab vedotin, in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, induced a 27% reduction in relative risk for disease progression, relapse, or death for patients with newly diagnosed diffuse large B-cell lymphoma.

Real-World Evidence On Shared Decision-Making Is Critical for Improving Patient Satisfaction in DLBCL

July 19th 2022

Integrating the lived experiences of patients with relapsed or refractory diffuse-large B-cell lymphoma into treatment-decision making should be a priority for practicing oncologists.

Pirtobrutinib Elicits 50% Response Rate in BTK-Pretreated MCL

July 19th 2022

Pirtobrutinib demonstrated potent antitumor activity and a low incidence of adverse effects in patients with BTK-pretreated and -naïve mantle cell lymphoma.

Zanubrutinib Represents Viable Treatment Option for Acalabrutinib-Intolerant B-cell Malignancies

July 19th 2022

Treatment with zanubrutinib maintained or improved response without an increase in acalabrutinib intolerance events in patients with previously treated B-cell malignancies.

CHOP-Based Combinations Represent Evolving Standard of Care in Frontline Treatment of PTCL

July 19th 2022

Neha Mehta-Shah, MD, MSCI, discusses frontline therapies in peripheral T-cell lymphoma, highlighting the current treatment landscape and the need to explore more treatment options in clinical trials.

BTK Inhibitor–Based Combinations May Improve the Efficacy of SOC Treatment in CNS Lymphoma

July 19th 2022

Avyakta Kallam, MBBS, discusses the benefits and shortcomings of the current standard of care in central nervous system lymphoma and expressed the importance of studying frontline targeted agents in this population.

Challenges in Making a Diagnosis of Acute GVHD

July 18th 2022

Focusing on acute graft versus host disease, panelists consider tools and methods that help to overcome challenges in making a differential diagnosis.

Educating Patients and Caregivers on the Impact of Graft Versus Host Disease

July 18th 2022

Expert perspectives on how best to educate patients and caregivers on graft versus host disease symptoms and quality of life.

Pirtobrutinib Demonstrates Encouraging Efficacy, Favorable Safety in Previously Treated CLL/SLL

July 14th 2022

Pirtobrutinib continued to produce promising responses in heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, irrespective of BTK C481 mutation status, reason for prior BTK inhibitor discontinuation, or other classes of previous therapy received.

Use of Rituximab Therapy in Chronic Immune Thrombocytopenia

July 14th 2022

Focusing on second-line systemic agents in immune thrombocytopenia, experts review the historical use of rituximab therapy.

What is the Role of Splenectomy in Chronic Immune Thrombocytopenia?

July 14th 2022

Panelists consider when they would select splenectomy over second-line systemic therapy in patients with immune thrombocytopenia.